» Articles » PMID: 24598804

Regulation of Macromolecular Modulators of Urinary Stone Formation by Reactive Oxygen Species: Transcriptional Study in an Animal Model of Hyperoxaluria

Overview
Specialties Nephrology
Physiology
Date 2014 Mar 7
PMID 24598804
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

We used an unbiased approach of gene expression profiling to determine differential gene expression of all the macromolecular modulators (MMs) considered to be involved in stone formation, in hyperoxaluric rats, with and without treatment with the NADPH oxidase inhibitor apocynin. Male rats were fed rat chow or chow supplemented with 5% wt/wt hydroxy-l-proline (HLP) with or without apocynin-supplemented water. After 28 days, rats were euthanized and their kidneys explanted. Total RNA was isolated and microarray analysis was conducted using the Illumina bead array reader. Gene ontology analysis and the pathway analyses of the genes were done using Database for Annotation, Visualization of Integrated Discovery enrichment analysis tool. Quantitative RT-PCR of selected genes was carried out to verify the microarray results. Expression of selected gene products was confirmed using immunohistochemistry. Administration of HLP led to crystal deposition. Genes encoding for fibronectin, CD 44, fetuin B, osteopontin, and matrix-gla protein were upregulated while those encoding for heavy chains of inter-alpha-inhibitor 1, 3, and 4, calgranulin B, prothrombin, and Tamm-Horsfall protein were downregulated. HLP-fed rats receiving apocynin had a significant reversal in gene expression profiles: those that were upregulated came down while those that were downregulated stepped up. Apocynin treatment resulted in near complete absence of crystals. Clearly, there are two types of MMs; one is downregulated while the other is upregulated during hyperoxaluria and crystal deposition. Apparently gene and protein expressions of known macromolecular modulators of CaOx crystallization are likely regulated by ROS produced in part through the activation of NADPH oxidase.

Citing Articles

From gut to kidney: microbiota modulates stone risk through inflammation-a mediated Mendelian randomization study.

Guo L, Lan Q, Zhou M, Liu F Mamm Genome. 2024; 36(1):250-261.

PMID: 39718578 DOI: 10.1007/s00335-024-10094-9.


Porous Se@SiO nanocomposites play a potential inhibition role in hyperoxaluria associated kidney stone by exerting antioxidant effects.

Ye C, Zhao L, Miao J, Gong C, Chen Y, Qin S Transl Androl Urol. 2024; 13(4):526-536.

PMID: 38721282 PMC: 11074679. DOI: 10.21037/tau-23-511.


Proposal for pathogenesis-based treatment options to reduce calcium oxalate stone recurrence.

Khan S, Canales B Asian J Urol. 2023; 10(3):246-257.

PMID: 37538166 PMC: 10394280. DOI: 10.1016/j.ajur.2023.01.008.


A spatially anchored transcriptomic atlas of the human kidney papilla identifies significant immune injury in patients with stone disease.

Canela V, Bowen W, Ferreira R, Syed F, Lingeman J, Sabo A Nat Commun. 2023; 14(1):4140.

PMID: 37468493 PMC: 10356953. DOI: 10.1038/s41467-023-38975-8.


The role of reactive oxygen species derived from different NADPH oxidase isoforms and mitochondria in oxalate-induced oxidative stress and cell injury.

Qian X, Wu W, Hu H, Yu X, Wang S, Zhu J Urolithiasis. 2022; 50(2):149-158.

PMID: 35128564 PMC: 8956535. DOI: 10.1007/s00240-022-01309-2.


References
1.
Khan S, Glenton P, Byer K . Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline. Kidney Int. 2006; 70(5):914-23. DOI: 10.1038/sj.ki.5001699. View

2.
Kok D . Clinical implications of physicochemistry of stone formation. Endocrinol Metab Clin North Am. 2002; 31(4):855-67. DOI: 10.1016/s0889-8529(02)00037-3. View

3.
Li N, Yi F, Spurrier J, Bobrowitz C, Zou A . Production of superoxide through NADH oxidase in thick ascending limb of Henle's loop in rat kidney. Am J Physiol Renal Physiol. 2002; 282(6):F1111-9. DOI: 10.1152/ajprenal.00218.2001. View

4.
Thongboonkerd V . Proteomics and kidney stone disease. Contrib Nephrol. 2008; 160:142-158. DOI: 10.1159/000125972. View

5.
Miyake O, Yoshioka T, Yoshimura K, Honda M, Yamaguchi S, Koide T . Expression of Tamm-Horsfall protein in stone-forming rat models. Br J Urol. 1998; 81(1):14-9. DOI: 10.1046/j.1464-410x.1998.00493.x. View